Mattias Mattsson, MD

Department of Hematology, University Hospital, Sweden

N/A

Poster(s):

• 1416 - CLL18 / MOIRAI: an international phase-III trial aiming to establish measurement of individual residual disease for adjustment of treatment duration to improve outcomes in first-line treatment of CLL/SLL

• 1441 - A functional prognostic model predicts progression free survival in patients with relapsed chronic lymphocytic leukemia treated with ibrutinib + venetoclax